secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001809519-25-000115
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q2 revenue $203.1M, Adj. EBITDA $69.4M; pharma segment up 32% YoY
------------------------------------------------------------------------

- Revenue $203.1M, net income $12.8M (6.3% margin); adjusted net income $33.9M (16.7% margin).
- Adjusted EBITDA $69.4M (34.2% margin); operating cash flow $49.6M.
- Pharma Manufacturer Solutions revenue +32% YoY; new pharmacy counter deals and ED subscription launched.
- Results in line with prior guidance; no explicit revision to outlook provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/0001809519-25-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000115/gdrx-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001809519-25-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer